Why is Brawn Biotech falling/rising?

As of 03-Jul, Brawn Biotech Ltd's stock price is currently at 20.00, reflecting an increase of 0.76 or 3.95%. The stock has shown a strong performance recently, gaining 23.76% over the past week and outperforming its sector by 4.01% today. It has been on a consecutive gain streak for the last five days and is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. However, despite this recent uptick, the company faces significant challenges, including operating losses and a weak long-term fundamental strength, with net sales declining at an annual rate of -22.97% and an operating profit decrease of -209.72% over the last five years. The company's ability to service its debt is also weak, as indicated by a poor EBIT to Interest ratio of -1.29.
In the broader market context, Brawn Biotech has underperformed significantly over the past year, with a return of -27.25% compared to the BSE500's positive return of 2.20%. While the stock has shown impressive short-term gains, its long-term performance remains concerning, as it has not only failed to keep pace with the market but also generated negative returns. This underperformance, coupled with the company's financial difficulties, suggests that while there may be short-term optimism reflected in the recent price increase, the overall outlook for Brawn Biotech remains precarious.